Abstract:The majority of therapies that target individual proteins rely on specific activity-modulating interactions with the target protein—for example, enzyme inhibition or ligand blocking. However, several major classes of therapeutically relevant proteins have unknown or inaccessible activity profiles and so cannot be targeted by such strategies. Protein-degradation platforms such as proteolysis-targeting chimaeras (PROTACs)<a href="/articles/s41586-020-2545-9#ref-CR1">1</a>,<a href="/articles/s41586-020-2545-9#ref-CR2">2</a> and others (for example, dTAGs<a href="/articles/s41586-020-2545-9#ref-CR3">3</a>, Trim-Away<a href="/articles/s41586-020-2545-9#ref-CR4">4</a>, chaperone-mediated autophagy targeting<a href="/articles/s41586-020-2545-9#ref-CR5">5</a> and SNIPERs<a href="/articles/s41586-020-2545-9#ref-CR6">6</a>) have been developed for proteins that are typically difficult to target; however, these methods involve the manipulation of intracellular protein degradation machinery and are therefore fundamentally limited to proteins that contain cytosolic domains to which ligands can bind and recruit the requisite cellular components. Extracellular and membrane-associated proteins—the products of 40% of all protein-encoding genes<a href="/articles/s41586-020-2545-9#ref-CR7">7</a>—are key agents in cancer, ageing-related diseases and autoimmune disorders<a href="/articles/s41586-020-2545-9#ref-CR8">8</a>, and so a general strategy to selectively degrade these proteins has the potential to improve human health. Here we establish the targeted degradation of extracellular and membrane-associated proteins using conjugates that bind both a cell-surface lysosome-shuttling receptor and the extracellular domain of a target protein. These initial lysosome-targeting chimaeras, which we term LYTACs, consist of a small molecule or antibody fused to chemically synthesized glycopeptide ligands that are agonists of the cation-independent mannose-6-phosphate receptor (CI-M6PR). We use LYTACs to develop a CRISPR interference screen that reveals the biochemical pathway for CI-M6PR-mediated cargo internalization in cell lines, and uncover the exocyst complex as a previously unidentified—but essential—component of this pathway. We demonstrate the scope of this platform through the degradation of therapeutically relevant proteins, including apolipoprotein E4, epidermal growth factor receptor, CD71 and programmed death-ligand 1. Our results establish a modular strategy for directing secreted and membrane proteins for lysosomal degradation, with broad implications for biochemical research and for therapeutics.

Small-Sized and Robust Chimaeric Lipopepsomes: A Simple and Functional Platform with High Protein Loading for Targeted Intracellular Delivery of Protein Toxin in Vivo

A bioinspired pseudopeptide-based intracellular delivery platform enhances the cytotoxicity of a ribosome-inactivating protein through multiple death pathways

Dynamically Crosslinked Nanocapsules for the Efficient and Serum-Resistant Cytosolic Protein Delivery

Lipopepsomes: A novel and robust family of nano-vesicles capable of highly efficient encapsulation and tumor-targeted delivery of doxorubicin hydrochloride in vivo

Smart polymersomes dually functionalized with cRGD and fusogenic GALA peptides enable specific and high-efficiency cytosolic delivery of apoptotic proteins.

Endocytosis‐independent and Cancer‐selective Cytosolic Protein Delivery via Reversible Tagging with LAT1 substrate

Simple and Efficient Targeted Intracellular Protein Delivery with Self‐Assembled Nanovehicles for Effective Cancer Therapy

Efficient intracellular delivery of proteins by a multifunctional chimaeric peptide in vitro and in vivo

Lysosome-targeting chimaeras for degradation of extracellular proteins

Charge-Selective Delivery of Proteins Using Mesoporous Silica Nanoparticles Fused with Lipid Bilayers.

Ph-Responsive Chimaeric Pepsomes Based on Asymmetric Poly(Ethylene Glycol)-B-Poly(L-Leucine)-B-Poly(L-Glutamic Acid) Triblock Copolymer for Efficient Loading and Active Intracellular Delivery of Doxorubicin Hydrochloride

Reduction and pH dual-bioresponsive crosslinked polymersomes for efficient intracellular delivery of proteins and potent induction of cancer cell apoptosis.

Biodegradable Chimaeric Polymersomes Mediate Highly Efficient Delivery of Exogenous Proteins into Cells

Optimization of Encapsulation Using Milk Polar Lipid Liposomes with S-Layer Protein and Transport Study of the ACE-Inhibitory Peptide RLSFNP

Conditional fusogenic lipid nanocarriers for cytosolic delivery of macromolecular therapeutics

A Tumor Microenvironment (Tme)-Responsive Nanoplatform for Systemic Saporin Delivery and Effective Breast Cancer Therapy.

GE11 peptide-installed chimaeric polymersomes tailor-made for high-efficiency EGFR-targeted protein therapy of orthotopic hepatocellular carcinoma

Efficient intracellular and in vivo delivery of toxin proteins by a ROS-responsive polymer for cancer therapy

Protein Toxin Chaperoned by LRP-1-Targeted Virus-Mimicking Vesicles Induces High-Efficiency Glioblastoma Therapy In Vivo.

Efficient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG co-modified liposomes.

Galactose-decorated reduction-sensitive degradable chimaeric polymersomes as a multifunctional nanocarrier to efficiently chaperone apoptotic proteins into hepatoma cells.